CA2792470A1 - Transdermal administration of peptides - Google Patents

Transdermal administration of peptides Download PDF

Info

Publication number
CA2792470A1
CA2792470A1 CA2792470A CA2792470A CA2792470A1 CA 2792470 A1 CA2792470 A1 CA 2792470A1 CA 2792470 A CA2792470 A CA 2792470A CA 2792470 A CA2792470 A CA 2792470A CA 2792470 A1 CA2792470 A1 CA 2792470A1
Authority
CA
Canada
Prior art keywords
cys
seq
trp
lys
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2792470A
Other languages
English (en)
French (fr)
Inventor
Patrick Bernard Deasy
Thomas Ciaran Loughman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Ipsen Manufacturing Ireland Ltd
Original Assignee
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Ipsen Manufacturing Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin, Ipsen Manufacturing Ireland Ltd filed Critical College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Publication of CA2792470A1 publication Critical patent/CA2792470A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2792470A 2010-03-25 2011-03-23 Transdermal administration of peptides Abandoned CA2792470A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE20100174A IE20100174A1 (en) 2010-03-25 2010-03-25 Transdermal administration of peptides
IE2010/0174 2010-03-25
PCT/IE2011/000019 WO2011117851A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides

Publications (1)

Publication Number Publication Date
CA2792470A1 true CA2792470A1 (en) 2011-09-29

Family

ID=44210069

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792470A Abandoned CA2792470A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides

Country Status (12)

Country Link
US (1) US20130085105A1 (OSRAM)
EP (1) EP2550005A1 (OSRAM)
JP (1) JP2013523629A (OSRAM)
KR (1) KR20130062275A (OSRAM)
CN (1) CN102883735A (OSRAM)
AU (1) AU2011231173A1 (OSRAM)
BR (1) BR112012022377A2 (OSRAM)
CA (1) CA2792470A1 (OSRAM)
IE (1) IE20100174A1 (OSRAM)
MX (1) MX2012010343A (OSRAM)
RU (1) RU2012145278A (OSRAM)
WO (1) WO2011117851A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
MX343499B (es) * 2010-03-15 2016-11-08 Ipsen Pharma Sas Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295637B2 (en) * 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
EP2979702A4 (en) * 2013-03-25 2016-11-16 Zeria Pharm Co Ltd GASTROKINETIC POSTPRANDIAL MEDIUM
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
PL3166967T3 (pl) * 2014-09-14 2023-07-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. Syntetyczne ligandy receptora somatostatyny
CA2984357A1 (en) 2015-04-29 2016-11-03 Radius Pharmaceuticals, Inc. Methods for treating cancer
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
KR20190005199A (ko) 2016-05-05 2019-01-15 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
KR101786914B1 (ko) * 2017-01-31 2017-11-15 주식회사 삼양사 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드
CN107226840A (zh) * 2017-05-04 2017-10-03 西安交通大学 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用
EP3687508A1 (en) * 2017-09-26 2020-08-05 Aquestive Therapeutics, Inc. Delivery pharmaceutical compositions including permeation enhancers
US11969460B2 (en) * 2018-06-08 2024-04-30 Saint Louis University Methods and compositions for treating decreased cognitive ability
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
IT201800009384A1 (it) * 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
CN119390714A (zh) 2019-02-12 2025-02-07 雷迪厄斯制药公司 方法和化合物
DE102020130492A1 (de) * 2020-11-18 2022-05-19 Lts Lohmann Therapie-Systeme Ag. Temperiersystem für eine Diffusionszelle, Diffusionszelle, Diffusionszellensystem, sowie Verfahren zur Temperierung in einer Diffusionszelle
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954975A (en) * 1972-02-17 1976-05-04 Ciba-Geigy Corporation Salts of ACTH-peptides and processes for their manufacture
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
EP0671937A4 (en) * 1992-10-16 1996-09-18 Smithkline Beecham Corp COMPOSITIONS FOR PHARMACEUTICAL EMULSIONS.
US6316414B1 (en) * 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
CA2450446A1 (en) * 2001-06-25 2003-01-03 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
WO2006040447A1 (fr) * 2004-10-07 2006-04-20 L'oreal Procédé de traitement cosmétique des fibres kératiniques et utilisation d'un inhibiteur de transglutaminase
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
WO2008008363A1 (en) * 2006-07-11 2008-01-17 Qps, Llc Pharmaceutical compositions for sustained release delivery of peptides
GB0705264D0 (en) * 2007-03-20 2007-04-25 Pliva Istrazivanje I Razvoj D Gel forming compounds
US20100196264A1 (en) * 2007-05-18 2010-08-05 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery

Also Published As

Publication number Publication date
BR112012022377A2 (pt) 2017-01-10
CN102883735A (zh) 2013-01-16
JP2013523629A (ja) 2013-06-17
RU2012145278A (ru) 2014-04-27
KR20130062275A (ko) 2013-06-12
WO2011117851A1 (en) 2011-09-29
EP2550005A1 (en) 2013-01-30
AU2011231173A1 (en) 2012-10-18
MX2012010343A (es) 2013-01-29
IE20100174A1 (en) 2012-02-29
US20130085105A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
US20130085105A1 (en) Transdermal Administration Of Peptides
JP6352806B2 (ja) 新規のグルカゴン類似体
Rivier et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists
TWI331922B (en) Growth hormone releasing peptides
US5604203A (en) Analogs of peptide YY and uses thereof
CN114349828A (zh) Glp-1/胰高血糖素受体双重激动剂及其应用
JPH09507217A (ja) 成長ホルモン放出特性を持つ化合物
JP2002542159A (ja) メラノコルチン受容体リガンド
IL302159A (en) GLP-1 drug inhibitors and uses thereof
SK155694A3 (en) Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
CA2335341A1 (en) Peptide analogues of pacap
CN116143884B (zh) 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
KR101399178B1 (ko) 선별가능한 특성을 갖는 하이브리드 폴리펩티드
LV12293B (en) Parathyroid hormone analogues for the treatment of osteoporosis
JP2000505105A (ja) ペプチドｙｙのアナログおよびその使用
WO2020077129A1 (en) Human amylin analog polypeptides and methods of use
Zarandi et al. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH)
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
JP2004513079A (ja) 鎮痛性ペプチドを含んでなる薬剤組成物
WO2025118962A1 (zh) 一类GLP-1受体、glucagon受体和GIP受体三激动多肽化合物及其应用
CN115226391A (zh) 胰高血糖素和glp-1受体的钉合三唑共激动剂
HK1180959A (en) Transdermal administration of peptides
CN115873096A (zh) 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用
CA3195872A1 (en) Glp-1 prodrugs and uses hereof
CN112608378A (zh) 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170323